A 67-year-old patient with a history of B-cell lymphoma of the abdomen has a bone marrow biopsy, but the specimen only yielded 11 metaphases that were identified for chromosome analysis. The report indicates 11 metaphases counted/analyzed and 2 metaphases karyotyped. Because the laboratory performed a chromosome analysis for a malignant hematological disorder with less than 20 cells, would it be appropriate to report code 88264 ? If yes, should modifier 52 be appended to code 88264 ? ...
Subscribe or sign in to view the full article.
Article Overview
This short coding Q&A focuses on chromosome analysis reporting for a malignant hematological disorder and discusses how specimen yield affects CPT code selection and modifier use. It is intended for coders, billers, and laboratory staff who need general guidance on interpreting a pathology/cytogenetics scenario involving reduced specimen output.
Why This Topic Matters
Laboratory cytogenetics coding depends on the scope of the work actually performed, and incomplete specimen yield can change both the reported CPT code and whether a modifier is used. Getting this right supports compliant claim reporting for oncology-related testing.
What You Will Learn
- How a hematology-related chromosome analysis scenario is evaluated for reporting purposes
- How specimen yield can affect the choice of a laboratory cytogenetics CPT code
- When a modifier may be considered in a reduced-services laboratory context
- How to interpret a short-form coding question and answer format
Who Should Read This
- Medical coders
- Pathology and laboratory billing staff
- Cytogenetics laboratory personnel
- Compliance teams
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com